Literature DB >> 17109785

Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

Shelley L Hyman1, E Arthur Shores, Kathryn N North.   

Abstract

Cognitive deficits are the most common complication in children with neurofibromatosis type 1 (NF1), and academic achievement is broadly affected. There is a lack of consensus in the literature regarding the frequency of general and specific learning disabilities, which seems to be related to the lack of a consensus on diagnostic criteria. The present study examined the frequency of specific learning disabilities (SLDs) in NF1, using an intellect-achievement discrepancy for diagnosis, as well as general learning difficulty associated with a lowering of general intellectual ability. The cohort consisted of 81 children with NF1 (43 males, 38 females; mean age 11y 6mo [SD 2y 4mo]; range 8y-16y 9mo) and 49 comparison children (20 males, 29 females; mean age 12y [SD 2y 6mo]; range 8y 2mo-16y 8mo). Problems with academic achievement were present in 52% of children with NF1; however, only 20% of the children with NF1 were diagnosed with an SLD (32% had more general learning problems). Only males with NF1 were at significant risk for SLD, and Verbal IQ<Performance IQ discrepancies were predictive of the presence of an SLD. There was a significant comorbidity of literacy-based learning disabilities and attention-deficit-hyperactivity disorder. We were able to define three subtypes of children with NF1 having distinct cognitive profiles, each with important implications for assessment and remediation.

Entities:  

Mesh:

Year:  2006        PMID: 17109785     DOI: 10.1017/S0012162206002131

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  58 in total

1.  Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.

Authors:  Sandra P Toelle; Andrea Poretti; Peter Weber; Tatjana Seute; Jacoline E C Bromberg; Ianina Scheer; Eugen Boltshauser
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  Teaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches.

Authors:  Laura A Barquero; Angela M Sefcik; Laurie E Cutting; Sheryl L Rimrodt
Journal:  Dev Med Child Neurol       Date:  2015-04-22       Impact factor: 5.449

Review 4.  The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research.

Authors:  Maria T Acosta; Carrie E Bearden; F Xavier Castellanos; Xavier F Castellanos; Laurie Cutting; Ype Elgersma; Gerard Gioia; David H Gutmann; Yong-Seok Lee; Eric Legius; Maximillian Muenke; Kathryn North; Luis F Parada; Nancy Ratner; Kim Hunter-Schaedle; Alcino J Silva
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

5.  Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.

Authors:  Kelly A Diggs-Andrews; Kazuhiro Tokuda; Yukitoshi Izumi; Charles F Zorumski; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 6.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

7.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

8.  Attitudes about internet support groups among adolescents and young adults with neurofibromatosis type 1 and their parents.

Authors:  Staci Martin; Pamela L Wolters; Andrea Baldwin; Marie Claire Roderick; Mary Anne Toledo-Tamula; Andrea Gillespie; Brigitte Widemann
Journal:  J Genet Couns       Date:  2014-01-28       Impact factor: 2.537

9.  Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network.

Authors:  Deborah A Bilder; Amanda V Bakian; David A Stevenson; Paul S Carbone; Christopher Cunniff; Alyson B Goodman; William M McMahon; Nicole P Fisher; David Viskochil
Journal:  J Autism Dev Disord       Date:  2016-10

Review 10.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.